|Bid||396.20 x 900|
|Ask||397.00 x 800|
|Day's Range||395.33 - 427.50|
|52 Week Range||223.25 - 468.55|
|Beta (5Y Monthly)||0.42|
|PE Ratio (TTM)||20.56|
|Earnings Date||Jul 20, 2021 - Jul 26, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||376.43|
Yahoo Finance's Anjalee Khemlani joins the Yahoo Finance panel to discuss the latest with Biogen as three members of the FDA panel resign over approval of Biogen’s Alzheimer’s drug: RPT
Julie Hyman breaks down Friday’s business headlines, including: A bipartisan group in the senate agreeing to an infrastructure bill that doesn’t have tax increases, a third member of the FDA advisory panel resigning over controversial approval of an Alzheimer’s drug, and two guest on a Royal Caribbean cruise testing positive for COVID-19 with asymptotic symptoms being quarantined.
When the U.S. Food and Drug Administration approved Aduhelm, (BIIB) (ticker: BIIB) Alzheimer’s disease therapy, this past Monday, it did so on the basis of the drug’s ability to reduce the level of junk proteins in patients’ brains. The agency believes that clearing those proteins, called amyloid plaques, reduces cognitive decline. Before the approval, few had thought that clearing amyloids was enough to get an Alzheimer’s therapy the green light from the FDA.